DR. EDWARD GERARD LAKATTA, M.D.
Osteopathic Medicine at Nathan Shock Dr, Baltimore, MD

8501925, Aug 6, 2013

Jan 5, 2010

12/652395

Li Lin - Baltimore MD, US
John Pang - Baltimore MD, US
Wen Wei - Cockeysville MD, US
Edward G. Lakatta - Bel Air MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Resources - Washington DC

C07H 21/04, C12Q 1/68

536 235, 435 61

Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins.

2012000, Jan 5, 2012

Feb 19, 2010

13/202319

Mingyi Wang - Baltimore MD, US
Zongming Fu - Baltimore MD, US
Edward G. Lakatta - Bel Air MD, US
Jennifer Van Eyk - Baltimore MD, US

C40B 30/04, G01N 33/53, G01N 27/447, C12Q 1/68

506 9, 435 61, 435 71, 435 612, 204456, 204451

Methods for determining if a subject has or is susceptible to having an age-associated vascular disorder are disclosed. The method includes determining if the subject exhibits altered expression of a product of one or more of the genes listed in Table 1 relative to a control level of expression of the gene product. Altered expression of one or more of the genes listed in Table 1 indicates that the subject has or is susceptible to having an age-associated vascular disorder. In specific examples the gene product is a product of the MFG-E8 and an increase in expression indicates the subject has or is susceptible to having an age-associated vascular disorder.

2012013, May 31, 2012

May 21, 2010

13/322066

Victor Maltsev - Parkville MD, US
Edward G. Lakatta - Bel Air MD, US
Syevda Sirenko - Baltimore MD, US
Maxim Milkheev - Clairton PA, US
Yoram Vodovotz - Sewickley PA, US

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda

A61K 35/34, A61P 9/06, C12N 5/10

424 9321, 435325

Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed.

2010015, Jun 24, 2010

Jun 26, 2006

11/993309

Alexei Bagrov - Cockeysville MD, US
Olga V. Fedorova - Lutherville MD, US
Edward G. Lakatta - Bel Air MD, US
Andrey Simbirtsev - St. Petersburg, RU
Alexander Kotov - St. Petersburg, RU
Nikolai Kolodkin - St. Petersburg, RU

C07K 16/18, C12N 5/16, C07K 16/46, G01N 33/566, A61K 39/395, A61P 9/00, A61P 9/12, A61P 9/10

4241331, 435346, 5303881, 5303913, 436501, 4241411, 5303873

Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject.